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Summary Differentiation inhibitory factor (nm23 protein) inhibited the induction of the differentiation of various leukaemic cell lines. We
previously reported that nm23 genes (Hi and H2) were overexpressed in acute myelogenous leukaemia (AML) and nm23-H1 expression
predicted the prognosis of AML, especially AML-M5. To clarify the correlation between French-American-British (FAB) classification and
nm23expression level and to clarify the involvement of nm23-H2and nm23-H1 in patient survival, we investigated the relative levels of nm23-
Hi and -H2 mRNA in 76 AML samples using the reverse transcriptase-polymerase chain reaction. We confirmed that the expression of both
nm23-Hl and -H2 genes in AML samples from three different hospitals was significantly higher than that in normal blood cells (P< 0.0005).
Overexpression of nm23-H1 was observed in each FAB AML-M1, -M2, -M3, -M4 or -M5 subtype, and the predictive effect of nm23-Hl
expression on AML prognosis was shown in FAB AML-M2 and -M5 cases. Although overexpression of nm23-H2was also found in each FAB
subtype, the expression of nm23-H2 in AML-M1 and -M3 cells was not significantly higher than that in normal cells. Among AML subtypes,
AML-M3 showed the lowest expression levels of both nm23 genes. To understand the relationship between nm23-H1 and -H2 expression
levels, nm23 expression levels for all the AML cases were plotted and divided into four groups (group A, nm23-H1 and -H2both high; B, both
low; C, only nm23-Hl high; D, only nm23-H2 high). A statistically significant correlation between the levels of expression of nm23-Hl and -H2
was observed (r= 0.726). Most AML-M3 cases belonged to group B, but not other types of AML. Analysis of survival probability between the
groups showed that group B survived for significantly longer compared with group A. Furthermore, AML-M3 cases survived for significantly
longer compared with non-M3 cases in the same group B. These data suggest that low expression levels of both nm23-Hl and -H2 are
associated with good prognosis in AML patients.
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The degree of differentiation is an important prognostic factor in
leukaemia. For example, patients with leukaemia of the undiffer-
entiated phenotype have a lower response rate to treatment and
poor survival. Induction of differentiation is closely linked to loss
of leukaemogenicity and blocks expression of the malignant
phenotypes. Conversely, a disorder of the cellular differentiation
of malignant cells reflects clinical behaviour and therapeutic
responses. Normal haematopoiesis can be controlled by various
positive and negative regulatory molecules. In myeloid leukaemia,
these signals continue to operate, but in an unbalanced fashion,
allowing emergence and eventual dominance ofa malignant clone.
Leukaemic cells are arrested in less differentiated stages of devel-
opment. These results suggest that negative regulators are also
important to regulate differentiation of leukaemic cells in addition
to positive regulators. We previously reported that a non-differen-
tiating mouse myeloid leukaemia cell line produced differentiation
inhibiting factors. Suppression of the production of the inhibitory
factors resulted in the non-differentiating leukaemic cells
becoming sensitive to differentiation inducers. One of the factors
was purified as a homologue ofnm23 (Okabe-Kado et al, 1992).
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Nm23 proteins are involved in tumour metastasis regulation and
have nucleoside diphosphate (NDP) kinase enzyme activity (Steeg
et al, 1988; De La Rosa et al, 1995). There are two types ofhuman
nm23 gene, namely nm23-HJ and nm23-H2. The proteins encoded
by nm23-H] and -H2 show 88% amino acid sequence homology
and the genes locate on the same region ofchromosome 17q21 in
tandem (Gilles et al, 1991; Stahl et al, 1991; Backer et al, 1993;
Chandrasekharappa et al, 1993; Okada et al, 1994). We found that
a differentiation inhibitory factor (I-factor) purified from a differ-
entiation-resistant mouse myeloid leukaemia cell line was iden-
tical to the nm23 protein (Okabe-Kado et al, 1992). The nm23-Hl
and -H2 proteins inhibited the induction of the differentiation of
mouse myelogenous leukaemia M1 and WEHI-3BD+ and human
erythroleukaemia HEL, KU812, and K562 cells. The I-factor
activity was independent of NDP kinase activity and required the
presence of the N-terminal 60 amino acids (Okabe-Kado et al,
1995a,b). Based on the biological activity of nm23 proteins for I-
factor, we previously investigated the relative levels of nm23-HI
and -H2 transcripts in AML and chronic myelogenous leukaemia
(CML) cells. nm23-H] and -H2 were overexpressed in AML but
not in CML in the chronic phase, and nm23-HJ expression
predicted the prognosis of AML, especially of AML-M5
(Yokoyama et al, 1996). In this study, we examined additional
cases of AML from a different hospital to confirm the clinical
implication of nm23-HJ expression on AML by multicentre
analysis, analysed the relationship between the expression ofboth
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Table 1 Levels of nm23-Hl and -H2 mRNA in normal and AML cells
FAB Number mRNA level (index ± s.d.) Ratio
classification of patients H1/H2
nm23-Hl nm23-H2
MO 2 23±12 45±40 0.51 (1.3)
Ml 14 105 ± 126** 132 ± 173 0.80 (2.0)
M2 21 105 ±99*** 101 ±75*** 1.04 (2.6)
M3 11 45±32** 74±62 0.61 (1.5)
M4 12 64±34*** 90±45** 0.71 (1.8)
M5 14 143 ±154*** 113 ±61 *** 1.28 (3.2)
M6 2 863 ± 538 525 ± 463 1.64 (4.1)
MO-M6 76 115 ± 177* 115 ± 129* 1.00 (2.5)
Normal 4 17 ± 7 43 ± 21 0.40 (1.0)
The mRNA levels were normalized for GAPDH mRNA. The positive control
(index=100) is represented by RNA extracted from the HEL cell line. Normal
samples include mononuclear cells of bone marrow and peripheral blood
obtained from four healthy donors. Values in parentheses are the ratios to
the normal value. Analysed by means of Student's t-test (vs normal).
*P < 0.0005; **P < 0.05; ***P < 0.01
Table 2 Clinical background and nm23 expression levels of 76 AML
patients
Clinical factors No. nm23-Hl P-value nm23-H2 P-value
Gender
Male 44 105 ± 99 106 ± 106
Female 32 127 ± 243 0.63 123 ± 182 0.62
Age (years)
Mean 50
Range 16-87
<50 38 122 ±146 114 ±118
>50 38 107 ±199 0.70 112 ± 137 0.93
WBC (x 1091-)
Mean 57.9
Range 0.7-485.5
<10 25 145 ±250 124 ±165
>10,<50 20 76 ±69 0.19 77 ±43 0.17
>50 24 126±146 0.13 131 ±136 0.07
Increased LDH
No 12 125 ±192 120 ± 142
Yes 58 85 ±102 0.32 79 ± 51 0.09
Values are means ± s.d. Analysed by means of Student's t-test.
nm23-HI and -H2, and evaluated combined data for nm23-H] and
-H2 as prognostic factors for AML.
MATERIALS AND METHODS
Clinical samples
Bone marrow (BM) samples from 76 patients with newly diag-
nosed acute myelogenous leukaemia (AML) were obtained at
onset with their informed consent and before chemotherapy. The
76 samples include those from an additional 34 patients in the
National Defense Medical College Hospital and 42 patients in the
hospitals of Showa University School of Medicine and Saitama
Cancer Center previously reported (Yokoyama et al, 1996). AML
was classified according to the criteria devised by the
French-American-British (FAB) Committee. In short, AML are
divided into acute myeloblastic leukaemia without (MO), with
minimal (Ml) and with further (M2) granulocytic differentiation,
acute hypergranular promyelocytic leukaemia (M3), acute
myelomonocytic leukaemia (M4), acute monocytic/monoblastic
leukaemia (M5), acute erythroleukaemia (M6) and acute
megakaryoblastic leukaemia (M7). Patients were treated with
cytosine arabinoside (or behenoyl cytosine arabinoside), dauno-
rubicin, with or without prednisolone and/or 6-mercaptopurine,
and AML-M3 patients were consecutively treated with all-trans
retinoic acid for remission induction therapy (AML-87 study of
the Japan Adult Leukemia Study Group, 1993; Ohno R et al,
1994). Treated patients were judged to be in complete remission
(CR) when bone marrow aspirates showed trilineage regeneration
with less than 5% blasts by morphological and immunocytochem-
ical analysis, in the presence of a normal blood count that persisted
for at least 1 month. Patients who died of toxic complications
(infection or bleeding) before the time of expected marrow
recovery were not evaluated. All other patients were considered
non-responsive (NR). To purify leukaemic cells, heparinized BM
aspirates were mixed with an equal volume of RPMI-1640
medium and centrifuged on Ficoll-Hypaque (Pharmacia, Uppsala,
Sweden) or Lymphoprep (Nycomed Pharma, Oslo, Norway). Total
RNA was extracted as described by Chomczynski and Sacchi
(1987), using guanidium thiocyanate.
Reverse transcriptase-polymerase chain reaction
(RT-PCR)
Quantitative RT-PCR was performed using a GeneAmp
RNA PCR kit (TaKaRa, Tokyo, Japan). The oligonucleotides used
in PCR amplification were as follows: sense strand, 5'-
ATGGCCAACTGTGAGCGTACC-3'; antisense strand, 5'-
CATGTATTTCACCAGGCCGGC-3' for nm23-HJ; sense strand,
5'-ATGGCCAACCTGGAGCGCACC-3', antisense strand, 5'-
TCCCCACGAATGGTGCCTGGC-3' for nm23-H2; sense strand,
5'-ACATCGCTCAGACACCATGG-3', antisense strand, 5'-
GTAGTTGAGGTCATGAAGGG-3' for GAPDH. Based on the
sequence information around the intron-exon junctions of each
gene, the primers were designed to sandwich one intron and, thus,
to specifically detect mRNA. RNA (0.2 ,ug) was reverse tran-
scribed to synthesize cDNA using random nonamers at 42°C, then
amplified by means of the PCR using specific primers (4 pmol)
and 0.11 Mbq of [cC-32P]dCTP (110 Tbq mmol-') in 20-gl mixtures
consisting of 10 mM Tris-HCl (pH 8.3), 50 mm potassium chlo-
ride, 1.2 mm magnesium chloride and 0.2 mm dNTPs (dATP,
dTTP, dGTP, dCTP). The PCR comprised 35 cycles for nm23-HJ
and 25 for nm23-H2 and GAPDH, with denaturing at 95°C for 1
min, annealing at 60°C for 1 min and extension at 72°C for 0.5
min. The reaction was performed in a GeneAmp PCR system 9600
(Perkin Elmer, Norwalk, CT, USA). The PCR products were then
subjected to 6% polyacrylamide gel electrophoresis, and the
radioactivity level in the dried gel was evaluated by means of
autoradiography using a Fuji Bio-Image Analyzer BAS2000 (Fuji
Film, Tokyo, Japan). The linearity of the quantitation of RT-PCR
products of nm23-HI, nm23-H2 and GAPDH was determined as
previously described (Yokoyama et al, 1996). To normalize the
differences in RNA loading for RT-PCR and RNA degradation in
individual samples, the values of the nm23-H] and -H2 gene
expression were divided by that of the GAPDH gene for compar-
ison with the values in erythroleukaemia HEL cells defined as 100
(the expression index).
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Table 3 FAB classification and levels of nm23-H1 and -H2 mRNA of AML cells
Student's t-test nm23-Hl P-value nm23-H2 P-value
Ml vs non-Mi 105 ± 12 vs 117 ± 183 0.77 132 ± 173 vs 109 ± 115 0.63
M2 vs non-M2 105 ±99 vs 118± 195 0.70 101 ±75 vs 117± 142 0.52
M3 vs non-M3 45 ± 32 vs 126± 185 0.002 74 ± 62 vs 120± 134 0.08
M4 vs non-M4 64 ± 34 vs 124± 187 0.02 90 ± 45 vs 117± 137 0.21
M5 vs non-M5 143 ± 154 vs 108± 178 0.47 113 ±61 vs 113± 138 1.00
The mRNA levels and the number of patients are shown in Table 2.
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Figure 1 Nm23-H1 and -H2 expression levels in AML patients. AML-M3
cases are represented by closed circles. Nm23-H1 expression shows a
strong positive correlation with nm23-H2 expression (r= 0.762)
Statistical analysis
Statistical comparisons between groups were performed by means
of Student's t-test, and values of P < 0.05 were considered signifi-
cant. Survival curves of patients were prepared using the
Kaplan-Meier method, and statistical analysis of the difference
between the survival curves was undertaken using the log-rank tests.
RESULTS
We examined nm23-HJ and -H2 mRNA expression levels of an
additional 34 AML cases from the National Defence Medical
College Hospital, Japan. Expression levels of nm23-HJ and -H2
genes in these AML cases were significantly higher than that in
normal blood cells (Student's t-test, P < 0.01). Elevated nm23-HJ
mRNA levels were associated with significantly reduced overall
survival (log-rank test, P < 0.05). These results using AML
samples from another centre confirm our previous findings. We
combined the present data with previous data for further analysis
ofthe clinical implication ofnm23 mRNA overexpression.
Levels of nm23-H1 and -H2expression and FAB
classification of AML patients
Data for 76 AML samples were available and we were able to
analyse the relationship between the levels of nm23-HJ and -H2
Table 4 Classification of 76 AML patients by the levels of nm23-Hl and -H2
mRNA
FAB Number Group
of patients
A B C D
MO 2 0 2 (100) 0 0
Ml 14 4 8 (57) 1 1
M2 21 7 12 (57) 1 1
M3 11 0 10 (91) 0 1
M4 12 0 7 (58) 1 4
M5 13 3 5 (39) 5 1
M6 2 2 0 (0) 0 0
Total 76 16 (21) 44 (58) 8 (11) 8 (11)
CR 8/16 (50) 29/40 (73) 4/7 (57) 6/6 (100)
NR 8/16 (50) 11/40 (28) 3/7 (43) 0/6 (0)
CR, complete remission; NR, non-responsive. According to the levels of
nm23-Hl and -H2mRNA, 76 AML patients were divided into four groups
(Figure 2). Group A, nm23-Hl and -H2both high; group B, Hi and -H2 both
low; group C, Hi high, H2 low; group D, Hi low, H2 high. Numbers in
parentheses are percentages.
expression and FAB classification of AML patients, except for
AML-MO and -M6. Table 1 shows the levels ofnm23-HJ and -H2
mRNA in normal blood cells and AML cells ofeach FAB subtype.
The average levels of nm23-HJ and -H2 expressions in the AML
samples were significantly higher than that in normal blood cells
(P < 0.0005). The level of nm23-HJ expression was significantly
higherinthe AML-M1, -M2, -M3, -M4 and -M5 subtypes than that
in normal cells and the level of nm23-H2 expression was signifi-
cantly higher in AML-M2, -M4 and -M5 than that in normal cells.
Although AML-Ml and -M3 cases also had higher expression
levels ofnm23-H2, they were not statistically significantly higher.
In AML-M6 cases, extremely high expression levels ofboth nm23
genes were observed, but the statistical significance of this could
not be determined because only two cases were investigated. For
the same reason, the difference in expression levels between AML-
MO patients and normal subjects was not significant.
The clinical backgrounds and nm23-HJ and -H2 expression
levels of 76 AML patients are summarized in Table 2. There was
no significant difference in nm23-HJ and -H2 expression levels
between groups separated based on gender, age, initial white blood
cell count and initial LDH level. Thus, we confirmed that the
nm23-HJ and -H2 expression levels in all the AML patients were
significantly higher than that in normal subjects, and we observed
the overexpression of both nm23 genes in the AML-M2, -M4
and -MS subtype. AML-M1 and -M3 samples also exhibited over-
expression of nm23-HJ mRNA, but the increase in nm23-H2
mRNA levels was not statistically significant.
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Figure 2 Comparison of survival period in two groups of M2 cases. Patients
with high nm23-H1 expression levels (> 100) (n = 8) had a worse prognosis
than those with low nm23-H1 expression levels (<100) (n = 11) (Student's
t-test, P = 0.0026). The survival period of AML-M2 patients with t (8,21)
(n = 10) was not statistically different from those without t (8,21) (n = 9)
(P= 0.0735)
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Figure 3 Kaplan-Meier survival curve of group A and B. Group A and B,
refer to Figure 1. (A) Comparison of survival curve of group A and B.
(B) Comparison of survival curve of group A, group Bi (AML-M3 cases) and
group B2 (non-M3 AML cases). Results of log-rank test are as follows: group
A vs B, P < 0.005; group B1 vs B2, P < 0.05; group A vs Bi, P < 0.01; group
A vs B2, P < 0.05
Table 3 shows a comparison ofthe nmn23-H1 and -H2 expression
levels in AML-FAB subtypes. The nm23-H] expression level in
AML-M3 and -M4 was significantly lower than that in the other
FAB types. Furthermore, AML-M3 exhibited the lowest expression
Table 5 Comparisons of survival probability between the four groups
divided by the expression levels of nm23-H1 and -H2
Log-rank test P-value Result
Group A vs B 0.01 < P < 0.005 P < 0.005
Group A vs C 0.50 < P < 0.75 NS
GroupAvs D 0.10 < P< 0.25 NS
GroupBvsC 0.10<P<0.25 NS
Group B vs D 0.95 < P < 1.0 NS
Group C vs D 0.25 < P < 0.50 NS
Group (A+C) vs (B+D) 0.005 < P < 0.01 P < 0.01
Group (A+D) vs (B+C) 0.05 < P< 0.10 NS
NS, not significant.
level ofnm23-H2 and nmn23-HJ (Table 1 and 3). To understand the
relationship between nm23-HI and -H2 expression levels, the
nm23 expression levels of all the AML cases were plotted and
divided into four groups; both nm23-HJ and -H2 are high in group
A, both are low in group B, only nm23-HI is high in group C and
only nm23-H2 is high in group D (Figure 1). The cut-off value in
nm23-HI is 100 and in nm23-H2 it is 120, as reported previously
(Yokoyama et al, 1996). There are 44 cases in group B (58%), 16
cases in group A (21%), eight cases in group C (11%) and eight
cases in group D (11%) (Table 4). Most AML-M3 cases (10 out of
1) belong to group B (91% of AML-M3 cases), while 57% ofMl,
57% of M2, 58% of M4 and 39% of M5 cases belong to group B
(Figure 1 and Table 4). Thus AML-M3 cases were characterized by
lower expression levels of both nm23-HI and -H2 than were the
other FAB types.
Classification by nm23-H1 and -H2expression levels
and survival of AML patients
We previously found that the nm23-HI mRNA level, but not the
nm23-H2 mRNA level, was associated with sensitivity to initial
chemotherapy and the survival of patients with AML, especially
AML-M5 (Yokoyama et al, 1996). Here we have confirmed that
AML-M5 patients (six M5 cases) with low nm23-HI expression
levels under 100 exhibited significantly higher rates of survival
than those (eight M5 cases) with higher levels over 100 (log-rank
test, P < 0.025). We also found that elevated nm23-HJ mRNA
levels were associated with significantly reduced survival of
AML-M2 patients (high eight M2 cases vs low 11 M2 cases),
while the presence oft(8;21) in AML-M2 patients was not associ-
ated with the overall survival (Figure 2). It is widely accepted that
patients with t(8;21) have a better remission rate than the mean for
other subjects, but there was no statistical difference in overall
survival in our study. A similar result was not obtained in AML-
M1 patients (high five M1 cases vs low nine MI cases, log-rank
test, P < 0.99). We could not analyse the AML-M3 and -M4 cases
because there were few or no cases with nm23-HJ expression
levels higher than 100. Thus, these results indicate that the nm23-
H] mRNA level is a prognostic factor not only for AML but also
for AML-M2 and -M5 subtypes.
We observed a strong correlation between nm23-HJ and -H2
expression levels in AML (r = 0.726, Figure 1), although we have
previously reported that nm23-H] but not -H2 was a prognostic
factor for AML. Therefore we analysed the involvement of the
nm23-H2 mRNA expression level in the chemotherapy sensitivity
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and survival probability of patients. As shown in Table 4, the CR
ratios of groups A, B, C and D were 50%, 73%, 57% and 100%
respectively. Although the groups with higher expression levels of
nm23-HJ (group A + C) showed lower CR ratios than did the other
groups, the CR ratio ofgroup A was similar to that ofgroup C. The
CR ratios of the groups with higher expression levels of nm23-H2
(group A + D) were similar to those ofthe other groups. The sensi-
tivity to initial chemotherapy seems to be associated with the nm23-
H] expression level rather than the nm23-H2 expression level.
Next, we compared the survival probability between the four
groups; group A vs B, A vs C, A vs D, B vs C, B vs D and C vs D.
Group B exhibited significantly longer survival times compared
with group A (log-rank test, P < 0.005, Figure 3A and Table 5),
although the comparisons between all the other groups indicated
no significant difference in survival time (Table 5). When we
compared the survival probability between the two groups divided
by nm23-HJ expression levels (group A+C vs group B+D), group
B+D exhibited significantly longer survival times than did group
A+C (log-rank test, P < 0.01, Table 5). The survival probability
between the two groups divided by nm23-H2 expression levels
(group A+D vs group B+C) seems to be different, but the
difference was not statistically significant (log-rank test,
0.05 < P < 0.10, Table 5). These results indicate that lower expres-
sion levels of both nm23-H] and -H2 is a better prognostic factor
than that ofonly nm23-Hl, as the P-value obtained by the log-rank
test of A vs B is higher than that of A+C vs B+D. As described
above, most AML-M3 cases belong to group B, and this group
exhibited significantly longer survival times than did group A
(log-rank test P < 0.005, Figure 3A). AML-M3 cases in group B
(group B1) exhibited significantly longer survival times in
comparison with non-M3 cases in the same group (group B2, log-
rank test, P < 0.05). The survival times of group B2 are statisti-
cally longer than those ofgroup A (log-rank test, P < 0.05, Figure
3B), suggesting that lower expression levels ofboth nm23-HJ and
-H2 are associated with good prognosis in AML. In the AML-M3
cases, there may be other factors regulating the abnormal growth
and differentiation ofthe leukaemic cells.
DISCUSSION
nm23-H] was discovered on the basis of its reduced expression
level in highly metastatic murine melanoma cell lines, compared
with related, weakly metastatic melanoma cell lines (Steeg et al,
1988). nm23-H2, a closely related gene, was identified by cross-
hybridization with nm23-HI on screening of a human fibroblast
cDNA library (Stahl et al, 1991). Reduced nm23-HJ expression
levels have been correlated with reduced patient disease-free or
overall survival time or other histopathological indicators of high
metastatic potential in cohorts of breast, ovarian, cervical, gastric
and hepatocellular carcinoma and melanoma. However, the
opposite trend has been identified in neuroblastoma, pancreatic
carcinoma, lymphoma and leukemia (De La Rosa, 1995). We
previously reported that nm23-HI and nm23-H2 were overex-
pressed in AML and the higher significance ofnm23-HJ expres-
sion correlated with a poor prognosis in AML. It has also been
reported that among malignant lymphomas, high-grade non-
Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma samples
exhibited significantly higher nm23-HJ expression levels than did
low-grade NHL samples. These studies suggest that nm23-H]
expression in human haematopoietic malignancies is associated
with disease aggressiveness. In this study, we confirmed the clin-
ical implication ofnm23-HJ expression for AML on a larger scale
than in our previous study and clarified the involvement ofnm23-
H2 expression levels on the prognosis ofAML, as nm23-H2 was
also significantly overexpressed in AML (Table 1), and a statisti-
cally significant correlation between the levels of expression of
nm23-H] and -H2 was observed in AML (Figure 1). As reported
previously for the 42 AML cases, the overall survival ofthe AML
patients with a high (>100) or low (<100) nm23-H2 index was not
statistically different (P = 0.6384), even when the cut-off points
were varied. In this study of76 AML cases, the overall survival of
the AMLpatients with a low nm23-H2 index (group B+C) was not
significantly higher than those with a high nm23-H2 index (group
A+D), although the P-value came close to being significant
(0.05 < P < 0.10) (Table 5). Group B (both expression levels low)
exhibited significantly longer survival times than did group A
(both expression levels high) (log-rank test, P < 0.005, Figure 3A
and Table 5). These results suggest that the nm23-H2 expression
level may be a weak prognostic factor for AML and the combina-
tion of nm23-H2 and nm23-H] expression is a better prognostic
factor than only nm23-HJ expression alone.
Based on analysis ofthe promoter regions ofnm23-HJ and -H2,
it is suggested that both nm23 genes are independently and differ-
entially regulated (Okada et al, 1996). However, a significant
correlation between the levels of expression of nm23-HJ and -H2
was observed in AML (Figure 1). Interestingly, group D seemed to
have a good response to the first chemotherapy and 50% of group
D were AML-M4 cases (Table 4). The ratio ofnm23-HJ to nm23-
H2 expression levels may provide useful information, as the ratio
(Hl/H2) in total AML was higher than that for normal blood cells
and similar to that for the HEL leukaemic cell line, and the ratio in
AML-M3 and -M4 cases is close to that of normal cells (Table 1).
In this study, we also clarified the correlation of nm23 expres-
sion levels with FAB classification (Table 1 and Table 3). Among
AML subtypes, AML-M5 showed relatively higher expression
levels than did the other FAB subtypes, although the difference in
nm23 expression levels between M5 and non-M5 AML was not
statistically significant (Table 3). On the other hand, we have
found that AML-M3 cases have the lowest nm23 expression
levels, a lower HI/H2 ratio and better prognosis in comparison
with the other FAB subtypes in AML. The low expression ofnm23
in AML-M3 may be associated with granulocytic differentiation-
associated characteristics and with potential to differentiate into
mature cells with all-trans retinoic acid (ATRA). nm23 proteins
were purified as differentiation inhibitory factors from non-
differentiating myeloid leukaemia cells (Okabe-Kado et al, 1992).
Yamashiro et al (1994) have reported that down-regulation of
nm23 gene expression is observed during the induced differentia-
tion of some human leukaemia cell lines. These results suggest
that AML-M3 cells are at a certain stage of granulocytic matura-
tion and down-regulation of nm23 gene expression accompanies
the maturation. It remains to be determined whether inhibition of
nm23 expression affects the induction of the differentiation of
leukaemia cells.
AML-M6 (erythroleukaemia) cases had extremely high expres-
sion levels of both nm23 genes and the ratio (Hl/H2) was also
extremely high, although only two cases were investigated (Table
1). It would be interesting to clarify whether the erythroid differ-
entiation-associated properties are related to the overexpression of
nm23 genes.
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Recently the nm23 protein was reported to have a specific inter-
action with ROR/RZR nuclear receptors (Paravicini et al, 1996),
and the interaction required the presence of the N-terminal 60
amino acids of the nm23 protein predicted to be important for the
I-factor activity of nm23 protein (Okabe-Kado et al, 1995). The
receptors for the retinoids are prominent members of the nuclear
receptor superfamily and RORIRZR receptors have been identi-
fied by homology cloning. They are known as orphan receptors,
referring to the fact that their ligands are unknown. RORa is
expressed in a variety oforgans with the highest levels of specific
mRNA detected in leucocytes. It is of interest to examine the
expression levels of RORa in leukaemia cells. Although the
biological implication of ROR/RZR is unknown, it is tempting to
speculate that retinoic acid receptor (RAR) and/or other nuclear
receptors might interact with the nm23 protein and participate in
the down-regulation of nm23 expression. A good prognosis in
AML-M3 is not solely related to nm23 expression, as the survival
times of AML-M3 cases were much longer than those of non-M3
AML cases in the same low nm23 expression level group (Figure
3). AML-M3 is associated with a consistent t(l5; 17) translocation
that fuses the promyelocytic leukaemia (PML) gene to the RARax
gene. Although the PML-RAR fusion protein is a majorprognostic
factor in AML-M3, the translocation (15;17)(q22;ql2) found in
AML-M3 might affect the expression of nm23 genes located on
chromosome 17q21. We are now examining whether the levels of
nm23 expression affect the sensitivity of AML-M3 patients to
ATRA treatment and whether they change during the disease
progression of AML-M3 patients.
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